FDA asked again to approve apomorphine pump SPN-830

Supernus Pharmaceuticals has asked the U.S. Food and Drug Administration (FDA) again to approve the apomorphine infusion pump SPN-830 for treating Parkinson’s disease. “We look forward to continuing our effort with the FDA throughout the NDA [new drug application] review process to bring a promising alternative to…

Supernus again will seek FDA OK of apomorphine infusion device

Supernus Pharmaceuticals plans to resubmit its application seeking approval of SPN-830, its apomorphine infusion pump for people with Parkinson’s disease, to the U.S. Food and Drug Administration (FDA) by the end of this year. The decision comes after a meeting with the FDA last month at which…